Chinese drugmakers' 2026 overseas licensing deals just hit $139 bln, ​beating last year's record. As ​Big Pharma turns to the ⁠country's labs for breakthroughs from ​cancer to obesity, rising stars ​like $44 bln Hengrui Pharma are capturing more of the upside from their discoveries.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in